-
Media Release
Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
-
Media Release
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer
-
Media Release
Video: Major Independent Trial Demonstrates Significant Anticancer Benefit of Zometa® in Women With Early-Stage Breast Cancer
-
Media Release
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
-
Media Release
RAD001 More Than Doubles Time Without Tumor Growth After Failure of Standard Treatment in Patients With Advanced Kidney Cancer
-
Media Release
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
-
Media Release
Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting
-
Media Release
VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
-
Media Release
VIDEO: Femara® helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
-
Media Release
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
-
Media Release
Everolimus (RAD001) Significantly Extends Progression-Free Survival in Advanced Kidney Cancer Patients After Failure of Other Targeted Therapy
-
Media Release
Video and Photo: Tekturna HCT®, a Single-tablet Combination of Tekturna®* and a Diuretic, Receives US Approval for Treatment of High Blood Pressure